{"success":true,"data":{"pressRelease":{"id":"168790","rtpr_id":"nBwc0NFGLa-20261014","ticker":"PEPT","exchange":"","all_tickers":["PEPT"],"title":"REX Shares Launches REX Peptide ETF (PEPT)","author":"Business Wire","published_at":"2026-10-14T12:00:00.813Z","article_body":"REX Shares Launches REX Peptide ETF (PEPT)\n\nNew thematic ETF targets the full peptide value chain: the drug developers,\nmanufacturers, delivery specialists, and consumer brands behind today’s\nGLP-1 treatments and the pipeline forming beyond obesity, in one globally\ndiversified trade.\n\nREX Shares (“REX”), a leading innovator in alternative ETFs, today\nannounced the launch of the REX Peptide ETF (Ticker: PEPT), a thematic ETF\nbuilt to own the peptide economy end to end. PEPT holds the companies that\ndevelop, manufacture, deliver, and commercialize peptide-based products,\nexpanding investor exposure beyond the two drugmakers that dominate today’s\nGLP-1 market. It is REX’s third thematic ETF, following the REX Drone ETF\n(DRNZ) and the REX AI Chipmaking ETF (CHIP).\n\nPeptides are the body’s own signaling molecules, re-engineered into precise,\nscalable medicines. They are the technology behind today’s GLP-1 treatments\nand a growing pipeline of therapies well beyond obesity, spanning metabolic\ndisease, cardiovascular indications, oncology, and rare disease. Most\nportfolios hold peptide exposure only through Eli Lilly and Novo Nordisk. In\naddition to those two names, PEPT owns the developers, manufacturers, and\nplatforms behind them. Wherever the next generation of peptide treatment\nleads, it still has to be commercialized, manufactured, and delivered, and\nthose are the parts of the chain PEPT touches.\n\nThe launch comes early in the adoption curve. Only about 2% of the world’s\nobese population is treated with GLP-1 medications today(1), while the share\nof U.S. adults taking a GLP-1 for weight loss has risen from 3% in 2024 to 11%\nin 2026(2). J.P. Morgan Global Research forecasts the global incretin market,\nwhich includes GLP-1s, reaching $200 billion by 2030(1), and Morgan Stanley\nResearch expects the market for GLP-1 treatments of obesity and type 2\ndiabetes to more than double from $79 billion in 2025 to $190 billion by\n2035(3). Supply is now the constraint: demand for peptide manufacturing is\noutrunning capacity, and PEPT owns the manufacturers building it.\n\n“Investors have spent three years expressing the GLP-1 trade through two\nstocks. The companies that develop, make, and deliver peptides are where the\nnext phase of growth has to run through,” said Greg King, CEO and Founder of\nREX Shares. “Whichever peptide wins the next indication, it still gets\nmanufactured and delivered by the same supply chain. PEPT is designed to give\ninvestors that whole chain in a single, globally diversified ticker.”\n\nThe ETF is based on the VettaFi Peptide Index, which tracks global companies\npositioned to advance the development, manufacturing, and commercial adoption\nof peptide-based products. The index spans four segments: therapeutics and\nmedicine, manufacturing and medical devices, nutraceuticals and supplements,\nand cosmeceuticals and skincare. Constituents must have a minimum market\ncapitalization of $100 million and a three-month average daily traded value of\nat least $1 million. The methodology allocates at least 80% of index weight to\npure-play companies deriving at least half of their revenue or research and\ndevelopment activity from peptides, with constituent caps limiting\nconcentration(4). As of 9.30.26, the index holds 36 constituents. By country,\nU.S. companies represent 52.9% of index weight and non-U.S. companies 47.1%.\n\nThe fund will be listed on Nasdaq under ticker symbol PEPT with an expense\nratio of 0.65%.\n\nFor full fund information, holdings, and risk disclosures, visit\nwww.rexshares.com/pept\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.rexshares.com%2Fpept&esheet=54621484&newsitemid=20261014005379&lan=en-US&anchor=www.rexshares.com%2Fpept&index=1&md5=b2f5c0127a6922aabbeb8a15bfa4623f)\n.\n\nSources\n\n1. J.P. Morgan Global Research, “How demand for (and supply of) weight loss\ndrugs is playing out in 2026,” February 2026.\n\n2. Gallup, “In U.S., GLP-1 Usage Reaches New High,” Gallup National Health\nand Well-Being Index, July 7, 2026 (updated September 8, 2026).\n\n3. Morgan Stanley Research, “Obesity Drugs Are Scaling Fast,” April 2026.\n\n4. VettaFi, Peptide Index methodology; REX ETF Trust, REX Peptide ETF\nprospectus dated October 10, 2026.\n\nAbout REX Shares\n\nREX Shares offers a suite of exchange-traded products built for both active\ntraders and long-term investors, spanning income, crypto, thematic, and\nleveraged strategies. Whether making short-term trades, generating income from\nvolatility, or investing in digital assets and emerging themes like drones, AI\nchipmaking, and peptides, REX empowers investors to act on strong market\nviews.\n\nImportant Information\n\nThe Fund is new and has no operating history, and the Index launched on\nSeptember 24, 2026. No performance is presented in this communication.\n\nThe Index's exposure to peptides may be indirect. Up to 20% of the Index may\nbe allocated to companies that derive less than half of their revenue or\nresearch and development activity from peptide-related operations, and\nconstituents may derive significant revenues from broader pharmaceutical,\nhealth care, or consumer businesses. The Index's eligibility screen is a\nsegment and revenue screen, not a guarantee of peptide-related revenue.\n\nAn investment in the Fund entails risk, including possible loss of principal.\nThe Fund is not a complete investment program. It is important that investors\nreview the risks below and the risks described in the prospectus, and\nunderstand them, before making an investment in the fund.\n\nInvestors should consider the investment objectives, risk, charges, and\nexpenses carefully before investing. For a prospectus or summary prospectus\nwith this and other information about the REX Peptide ETF please call\n1-844-802-4004 or visit our website at rexshares.com.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Frexshares.com&esheet=54621484&newsitemid=20261014005379&lan=en-US&anchor=rexshares.com.&index=2&md5=fb4d896e60e7e840fbd0eaf35dbaf60a)\nRead the prospectus and summary prospectus carefully before investing.\n\nImportant Risks\n\nPeptide Industry Risk. Companies involved in the development, manufacturing,\nand commercialization of peptide-based products face intense competition,\nlengthy and uncertain regulatory approval processes, clinical trial failures,\npatent expirations, pricing and reimbursement pressure, and rapid product\nobsolescence. Their share prices may be more volatile than the broader market.\n\nBiotechnology, Pharmaceutical, and Health Care Sector Risk. The Fund invests\nin companies in the biotechnology, pharmaceutical, and health care sectors.\nThese businesses are heavily dependent on government approvals and regulation,\npatent protection, and the outcome of clinical trials, and can be materially\naffected by changes in health care policy, drug pricing legislation, supply\nchain disruption, manufacturing capacity constraints, and product liability\nclaims.\n\nConcentration Risk and Non-Diversification Risk. The Fund concentrates its\ninvestments in an industry or group of industries, and as a non-diversified\nfund it may invest a greater portion of its assets in the securities of a\nsingle issuer. Both increase the effect that any single holding or industry\ndevelopment has on the Fund's value.\n\nForeign Securities, Currency, Depositary Receipts, Europe and Asia Risk. The\nFund invests significantly in securities of non-US issuers, directly and\nthrough depositary receipts. Foreign investments involve risks not typically\nassociated with US investments, including currency fluctuation, different\nregulatory and accounting standards, less liquidity, higher transaction costs,\nand political and economic developments specific to a country or region. The\nIndex may have significant exposure to Europe and Asia.\n\nNew Fund, New Index, Index Provider, Passive Investment and Non-Correlation\nRisk. The Fund is recently organized and has no operating history. The Index\nis newly created and has a limited history. The Fund is not actively managed\nand relies on the Index Provider's methodology and data; errors in index\nconstruction or calculation may not be identified or corrected promptly. The\nFund's return may not match the Index's return.\n\nEquity, Large, Mid and Small Capitalization, Liquidity, Volatility, Trading\nIssues, Premium/Discount, Costs of Buying and Selling Fund Shares, Authorized\nParticipant and Operational Risk. Equity values rise and fall. Smaller\ncompanies may be more volatile and less liquid than larger companies. Shares\nmay trade at a premium or discount to net asset value, trading may be halted,\nand the Fund relies on a limited number of authorized participants and market\nmakers. Buying and selling shares involves brokerage and other costs.\n\nTotal annual fund operating expenses are 0.65%. The Adviser pays all Fund\nexpenses excluding the management fee, interest, taxes, acquired fund fees and\nexpenses, and brokerage commissions. See the prospectus for the full fee\ntable, the investment objective, and complete risk disclosures. The Fund is a\nseries of REX ETF Trust. The Fund's investment adviser is REX Advisers, LLC.\n\nThe VettaFi Peptide Index is a service mark of VettaFi LLC and has been\nlicensed for use by REX Shares, LLC and the REX Peptide ETF. The REX Peptide\nETF is not sponsored, endorsed, sold or promoted by VettaFi LLC and VettaFi\nLLC makes no representation regarding the advisability of investing in the REX\nPeptide ETF.\n\nDistributor: Foreside Fund Services, LLC, member FINRA, not affiliated with\nREX Shares or the Fund’s investment advisor.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261014005379/en/\n(https://www.businesswire.com/news/home/20261014005379/en/)\n\nFor media inquiries, please contact:\n\nGregory Agency for REX: rexfin@gregoryagency.com\n(mailto:rexfin@gregoryagency.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwc0NFGLa-20261014","title":"REX Shares Launches REX Peptide ETF (PEPT)","author":"Business Wire","ticker":"PEPT","created":"2026-10-14T12:00:00.813Z","tickers":["PEPT"],"exchange":"","article_body":"REX Shares Launches REX Peptide ETF (PEPT)\n\nNew thematic ETF targets the full peptide value chain: the drug developers,\nmanufacturers, delivery specialists, and consumer brands behind today’s\nGLP-1 treatments and the pipeline forming beyond obesity, in one globally\ndiversified trade.\n\nREX Shares (“REX”), a leading innovator in alternative ETFs, today\nannounced the launch of the REX Peptide ETF (Ticker: PEPT), a thematic ETF\nbuilt to own the peptide economy end to end. PEPT holds the companies that\ndevelop, manufacture, deliver, and commercialize peptide-based products,\nexpanding investor exposure beyond the two drugmakers that dominate today’s\nGLP-1 market. It is REX’s third thematic ETF, following the REX Drone ETF\n(DRNZ) and the REX AI Chipmaking ETF (CHIP).\n\nPeptides are the body’s own signaling molecules, re-engineered into precise,\nscalable medicines. They are the technology behind today’s GLP-1 treatments\nand a growing pipeline of therapies well beyond obesity, spanning metabolic\ndisease, cardiovascular indications, oncology, and rare disease. Most\nportfolios hold peptide exposure only through Eli Lilly and Novo Nordisk. In\naddition to those two names, PEPT owns the developers, manufacturers, and\nplatforms behind them. Wherever the next generation of peptide treatment\nleads, it still has to be commercialized, manufactured, and delivered, and\nthose are the parts of the chain PEPT touches.\n\nThe launch comes early in the adoption curve. Only about 2% of the world’s\nobese population is treated with GLP-1 medications today(1), while the share\nof U.S. adults taking a GLP-1 for weight loss has risen from 3% in 2024 to 11%\nin 2026(2). J.P. Morgan Global Research forecasts the global incretin market,\nwhich includes GLP-1s, reaching $200 billion by 2030(1), and Morgan Stanley\nResearch expects the market for GLP-1 treatments of obesity and type 2\ndiabetes to more than double from $79 billion in 2025 to $190 billion by\n2035(3). Supply is now the constraint: demand for peptide manufacturing is\noutrunning capacity, and PEPT owns the manufacturers building it.\n\n“Investors have spent three years expressing the GLP-1 trade through two\nstocks. The companies that develop, make, and deliver peptides are where the\nnext phase of growth has to run through,” said Greg King, CEO and Founder of\nREX Shares. “Whichever peptide wins the next indication, it still gets\nmanufactured and delivered by the same supply chain. PEPT is designed to give\ninvestors that whole chain in a single, globally diversified ticker.”\n\nThe ETF is based on the VettaFi Peptide Index, which tracks global companies\npositioned to advance the development, manufacturing, and commercial adoption\nof peptide-based products. The index spans four segments: therapeutics and\nmedicine, manufacturing and medical devices, nutraceuticals and supplements,\nand cosmeceuticals and skincare. Constituents must have a minimum market\ncapitalization of $100 million and a three-month average daily traded value of\nat least $1 million. The methodology allocates at least 80% of index weight to\npure-play companies deriving at least half of their revenue or research and\ndevelopment activity from peptides, with constituent caps limiting\nconcentration(4). As of 9.30.26, the index holds 36 constituents. By country,\nU.S. companies represent 52.9% of index weight and non-U.S. companies 47.1%.\n\nThe fund will be listed on Nasdaq under ticker symbol PEPT with an expense\nratio of 0.65%.\n\nFor full fund information, holdings, and risk disclosures, visit\nwww.rexshares.com/pept\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.rexshares.com%2Fpept&esheet=54621484&newsitemid=20261014005379&lan=en-US&anchor=www.rexshares.com%2Fpept&index=1&md5=b2f5c0127a6922aabbeb8a15bfa4623f)\n.\n\nSources\n\n1. J.P. Morgan Global Research, “How demand for (and supply of) weight loss\ndrugs is playing out in 2026,” February 2026.\n\n2. Gallup, “In U.S., GLP-1 Usage Reaches New High,” Gallup National Health\nand Well-Being Index, July 7, 2026 (updated September 8, 2026).\n\n3. Morgan Stanley Research, “Obesity Drugs Are Scaling Fast,” April 2026.\n\n4. VettaFi, Peptide Index methodology; REX ETF Trust, REX Peptide ETF\nprospectus dated October 10, 2026.\n\nAbout REX Shares\n\nREX Shares offers a suite of exchange-traded products built for both active\ntraders and long-term investors, spanning income, crypto, thematic, and\nleveraged strategies. Whether making short-term trades, generating income from\nvolatility, or investing in digital assets and emerging themes like drones, AI\nchipmaking, and peptides, REX empowers investors to act on strong market\nviews.\n\nImportant Information\n\nThe Fund is new and has no operating history, and the Index launched on\nSeptember 24, 2026. No performance is presented in this communication.\n\nThe Index's exposure to peptides may be indirect. Up to 20% of the Index may\nbe allocated to companies that derive less than half of their revenue or\nresearch and development activity from peptide-related operations, and\nconstituents may derive significant revenues from broader pharmaceutical,\nhealth care, or consumer businesses. The Index's eligibility screen is a\nsegment and revenue screen, not a guarantee of peptide-related revenue.\n\nAn investment in the Fund entails risk, including possible loss of principal.\nThe Fund is not a complete investment program. It is important that investors\nreview the risks below and the risks described in the prospectus, and\nunderstand them, before making an investment in the fund.\n\nInvestors should consider the investment objectives, risk, charges, and\nexpenses carefully before investing. For a prospectus or summary prospectus\nwith this and other information about the REX Peptide ETF please call\n1-844-802-4004 or visit our website at rexshares.com.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Frexshares.com&esheet=54621484&newsitemid=20261014005379&lan=en-US&anchor=rexshares.com.&index=2&md5=fb4d896e60e7e840fbd0eaf35dbaf60a)\nRead the prospectus and summary prospectus carefully before investing.\n\nImportant Risks\n\nPeptide Industry Risk. Companies involved in the development, manufacturing,\nand commercialization of peptide-based products face intense competition,\nlengthy and uncertain regulatory approval processes, clinical trial failures,\npatent expirations, pricing and reimbursement pressure, and rapid product\nobsolescence. Their share prices may be more volatile than the broader market.\n\nBiotechnology, Pharmaceutical, and Health Care Sector Risk. The Fund invests\nin companies in the biotechnology, pharmaceutical, and health care sectors.\nThese businesses are heavily dependent on government approvals and regulation,\npatent protection, and the outcome of clinical trials, and can be materially\naffected by changes in health care policy, drug pricing legislation, supply\nchain disruption, manufacturing capacity constraints, and product liability\nclaims.\n\nConcentration Risk and Non-Diversification Risk. The Fund concentrates its\ninvestments in an industry or group of industries, and as a non-diversified\nfund it may invest a greater portion of its assets in the securities of a\nsingle issuer. Both increase the effect that any single holding or industry\ndevelopment has on the Fund's value.\n\nForeign Securities, Currency, Depositary Receipts, Europe and Asia Risk. The\nFund invests significantly in securities of non-US issuers, directly and\nthrough depositary receipts. Foreign investments involve risks not typically\nassociated with US investments, including currency fluctuation, different\nregulatory and accounting standards, less liquidity, higher transaction costs,\nand political and economic developments specific to a country or region. The\nIndex may have significant exposure to Europe and Asia.\n\nNew Fund, New Index, Index Provider, Passive Investment and Non-Correlation\nRisk. The Fund is recently organized and has no operating history. The Index\nis newly created and has a limited history. The Fund is not actively managed\nand relies on the Index Provider's methodology and data; errors in index\nconstruction or calculation may not be identified or corrected promptly. The\nFund's return may not match the Index's return.\n\nEquity, Large, Mid and Small Capitalization, Liquidity, Volatility, Trading\nIssues, Premium/Discount, Costs of Buying and Selling Fund Shares, Authorized\nParticipant and Operational Risk. Equity values rise and fall. Smaller\ncompanies may be more volatile and less liquid than larger companies. Shares\nmay trade at a premium or discount to net asset value, trading may be halted,\nand the Fund relies on a limited number of authorized participants and market\nmakers. Buying and selling shares involves brokerage and other costs.\n\nTotal annual fund operating expenses are 0.65%. The Adviser pays all Fund\nexpenses excluding the management fee, interest, taxes, acquired fund fees and\nexpenses, and brokerage commissions. See the prospectus for the full fee\ntable, the investment objective, and complete risk disclosures. The Fund is a\nseries of REX ETF Trust. The Fund's investment adviser is REX Advisers, LLC.\n\nThe VettaFi Peptide Index is a service mark of VettaFi LLC and has been\nlicensed for use by REX Shares, LLC and the REX Peptide ETF. The REX Peptide\nETF is not sponsored, endorsed, sold or promoted by VettaFi LLC and VettaFi\nLLC makes no representation regarding the advisability of investing in the REX\nPeptide ETF.\n\nDistributor: Foreside Fund Services, LLC, member FINRA, not affiliated with\nREX Shares or the Fund’s investment advisor.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261014005379/en/\n(https://www.businesswire.com/news/home/20261014005379/en/)\n\nFor media inquiries, please contact:\n\nGregory Agency for REX: rexfin@gregoryagency.com\n(mailto:rexfin@gregoryagency.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-14T12:00:00.956322041Z","server_sent_at_ms":1791979200956},"received_at":"2026-10-14T12:00:01.010Z","source_url":"https://www.businesswire.com/news/home/20261014005379/en/"},"analysis":{"id":"157050","press_release_id":"168790","analysis_json":{"industry":{"label":"Capital Markets","sector":"Financials"},"redFlags":["new fund with no operating history; underlying index launched September 24, 2026","concentrated, non-diversified thematic exposure with sector volatility risk"],"eventType":"product_launch","narrative":"REX Shares launched the REX Peptide ETF (PEPT) on Nasdaq, a thematic fund targeting the full peptide value chain from drug developers to manufacturers and delivery specialists.\n\nThe fund tracks the VettaFi Peptide Index, holds 36 constituents as of 9.30.26 (52.9% U.S. weight), charges a 0.65% expense ratio, and requires constituents to have at least $100 million market cap with at least 80% of index weight in pure-play peptide companies.\n\nREX cites adoption-curve data — about 2% of the world's obese population on GLP-1s and forecasts of a $190-200B market by 2030-2035 — positioning PEPT as a play beyond the dominant Eli Lilly and Novo Nordisk duopoly.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"New thematic ticker for the GLP-1/peptide supply-chain trade beyond the Lilly/Novo duopoly."},"keyFigures":{"customDimensions":{"expense_ratio":"0.65%","min_market_cap":"$100 million","us_index_weight":"52.9%","index_constituents":36,"non_us_index_weight":"47.1%","pure_play_min_index_weight":"80%"}},"quotedText":"Investors have spent three years expressing the GLP-1 trade through two stocks. The companies that develop, make, and deliver peptides are where the next phase of growth has to run through","namedEntities":{"people":[{"name":"Greg King","role":"CEO and Founder of REX Shares"}],"products":["REX Peptide ETF (PEPT)","REX Drone ETF (DRNZ)","REX AI Chipmaking ETF (CHIP)","VettaFi Peptide Index"],"companies":[{"name":"REX Shares","relationship":"issuer/sponsor"},{"name":"REX Advisers, LLC","relationship":"investment adviser"},{"name":"VettaFi LLC","relationship":"index provider"},{"name":"Foreside Fund Services, LLC","relationship":"distributor"},{"name":"Eli Lilly","relationship":"index constituent/mention"},{"name":"Novo Nordisk","relationship":"index constituent/mention"}],"dollarAmounts":[{"amount":"$200 billion","context":"J.P. Morgan forecast for global incretin market by 2030"},{"amount":"$79 billion","context":"Morgan Stanley estimate of 2025 GLP-1 obesity/T2D market"},{"amount":"$190 billion","context":"Morgan Stanley forecast for GLP-1 market by 2035"},{"amount":"$100 million","context":"minimum constituent market capitalization"}]},"materialImpact":{"score":2,"reasoning":"Launch of a new thematic ETF is a routine product announcement for the issuer. It adds a new investable ticker but carries no earnings, regulatory, or balance-sheet consequences."},"tickerRelevance":{"others":[],"primary":"PEPT"},"globalImportance":18,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"new-launch ETF","issuerScale":"mid-size ETF sponsor","eventGravity":"product launch","retailFavoriteBoost":"GLP-1 theme has retail interest"}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"REX Shares launched the REX Peptide ETF (PEPT) on Nasdaq, a thematic fund targeting the full peptide value chain from drug developers to manufacturers and delivery specialists.\n\nThe fund tracks the VettaFi Peptide Index, holds 36 constituents as of 9.30.26 (52.9% U.S. weight), charges a 0.65% expense ratio, and requires constituents to have at least $100 million market cap with at least 80% of index weight in pure-play peptide companies.\n\nREX cites adoption-curve data — about 2% of the world's obese population on GLP-1s and forecasts of a $190-200B market by 2030-2035 — positioning PEPT as a play beyond the dominant Eli Lilly and Novo Nordisk duopoly.","key_figures":{"customDimensions":{"expense_ratio":"0.65%","min_market_cap":"$100 million","us_index_weight":"52.9%","index_constituents":36,"non_us_index_weight":"47.1%","pure_play_min_index_weight":"80%"}},"named_entities":{"people":[{"name":"Greg King","role":"CEO and Founder of REX Shares"}],"products":["REX Peptide ETF (PEPT)","REX Drone ETF (DRNZ)","REX AI Chipmaking ETF (CHIP)","VettaFi Peptide Index"],"companies":[{"name":"REX Shares","relationship":"issuer/sponsor"},{"name":"REX Advisers, LLC","relationship":"investment adviser"},{"name":"VettaFi LLC","relationship":"index provider"},{"name":"Foreside Fund Services, LLC","relationship":"distributor"},{"name":"Eli Lilly","relationship":"index constituent/mention"},{"name":"Novo Nordisk","relationship":"index constituent/mention"}],"dollarAmounts":[{"amount":"$200 billion","context":"J.P. Morgan forecast for global incretin market by 2030"},{"amount":"$79 billion","context":"Morgan Stanley estimate of 2025 GLP-1 obesity/T2D market"},{"amount":"$190 billion","context":"Morgan Stanley forecast for GLP-1 market by 2035"},{"amount":"$100 million","context":"minimum constituent market capitalization"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T12:00:12.518Z","global_importance":18,"audience_relevance":30,"importance_components":{"tickerTier":"new-launch ETF","issuerScale":"mid-size ETF sponsor","eventGravity":"product launch","retailFavoriteBoost":"GLP-1 theme has retail interest"}},"durationMs":6837,"modelName":"glm-5.3-flashx"}}